CXCR1 and neoplasm: Furthermore, Jamieson et al. showed that CXCR1/2-targeted pepducins could inhibit adenoma formation in APC(Min/+) mice, attributed to a reduction in neutrophil recruitment during tumor-inducing inflammation [77].